Vemurafenib for leptomeningeal melanomatosis

Journal of Clinical Oncology

Volumn 31, Issue 11, 2013, Pages

  Schäfer, Niklas ^a   Scheffler, Björn ^a   Stuplich, Moritz ^a   Schaub, Christina ^a   Kebir, Sied ^a   Rehkam̈per, Claudia ^a   Mack, Frederick ^a   Niehusmann, Pitt ^a   Simon, Matthias ^a   Greschus, Susanne ^a   Kuchelmeister, Klaus ^a   Herrlinger, Ulrich ^a   Glas, Martin ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; LACTIC ACID; LOMUSTINE; VEMURAFENIB;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; LEPTOMENINGEAL MELANOMATOSIS; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

FEMALE; HUMANS; INDOLES; MELANOMA; MENINGEAL NEOPLASMS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84876076565     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.5773     Document Type: Article

References (5)

1. Davies MA, Liu P, McIntyre S, et al: Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:1687-1696, 2011
2. Harstad L, Hess KR, Groves MD: Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol 10:1010-1018, 2008
3. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
4. Rochet NM, Kottschade LA, Markovic SN: Vemurafenib for melanoma metastases to the brain. N Engl J Med 365:2439-2441, 2011
5. Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012